|
|
||||||||
Division of Nuclear Medicine, Ottawa Civic Hospital, Ottawa, Canada
Correspondence: For reprints contact: J. R. Ballinger, PhD, Div. of Nuclear Medicine, Ottawa Civic Hospital, 1053 Carling Ave., Ottawa, Ontario, Canada, K1Y 4E9.
ABSTRACT
Variability in the quality of [99mTc]HM-PAO images of the brain has been attributed to differences between kits and the addition of excessive amounts of pertechnetate to the kits. A retrospective study showed no significant differences between batches of kits with respect to radiochemical purity (RCP) or image quality. Up to 3000 MBq (81 mCi) pertechnetate could be added to the kit without adversely affecting RCP or image quality. It was shown that image quality was directly affected by RCP at time of injection and dropped sharply when RCP fell below 85%. Interstitial injection and mixing with blood prior to injection also resulted in poor image quality. Pretreatment with perchlorate reduced uptake of activity in the parotid glands; this improved image quality and reduced the influence of RCP.
This article has been cited by other articles:
![]() |
I. L. Koslowsky, S. E. Brake, and S. J. Bitner Evaluation of the Stability of 99mTc-ECD and Stabilized 99mTc-HMPAO Stored in Syringes J. Nucl. Med. Technol., December 1, 2001; 29(4): 197 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Roca, F. Iglesias, V. García, F. Armero, and M C. Díaz Chemotaxis, Viability, and Labeling Stability of Leukocytes Labeled with 99mTc-Exametazime Stabilized with Methylene Blue J. Nucl. Med., March 1, 2001; 42(3): 505 - 508. [Abstract] [Full Text] |
||||
![]() |
J. Wolff Perchlorate and the Thyroid Gland Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |